


ABSTRACT

A compound of formula (1):



wherein each of R₁, R₂, R₄, R_{4'}, R₇, R₁₁, R₁₂, R₁₅, R₁₆, R₁₇, and R_{17'}, independently, is hydrogen, hydroxy, amino, carboxyl, oxo, halo, sulfonic acid, -O-sulfonic acid, or alkyl that is optionally inserted with -NH-, -N(alkyl)-, -O-, -S-, -SO-, -SO₂-, -O-SO₂-, -SO₂-O-, -SO₃-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-, and further optionally substituted with hydroxy, halo, amino, carboxyl, sulfonic acid, or -O-sulfonic acid; R₃ is X-Y-, wherein X is hydrogen, amino, carboxyl, halo, sulfonic acid, -O-sulfonic acid, or alkyl; Y is -S-, -NH-, -N(alkyl)-, -SO-, -SO₂-, -O-SO₂-, -SO₂-O-, -SO₃-O-, -CO-, -CO-O-, -O-CO-, -CO-NH-, -CO-N(alkyl)-, -NH-CO-, or -N(alkyl)-CO-; R₅ and R₆, together, are -O-; or R₅ and R₆, together, are a double bond between C-5 and C-6, and R₇ is oxo; each of R₈, R₉, R₁₀, R₁₃, and R₁₄, independently, is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, or amino; and n is 0, 1, or 2. Also disclosed are a method of treating hypocholesterolemia and a method of screening for an LXR agonist by administering a compound described above, a pharmaceutical composition containing at least one of the compounds described above, and an antibody against 5α, 6α-epoxycholesterol-3-sulfate or 7-ketocholesterol-3-sulfate.